Agios Pharmaceuticals, Inc. (AGIO) financial statements (2020 and earlier)
Company profile
| Business Address |
88 SIDNEY STREET CAMBRIDGE, MA 02139 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in millions)
| 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments, including: | 718 | 805 | 568 | 574 | 376 | 467 | 194 | ||
| Cash and cash equivalents | 81 | 71 | 103 | 161 | 72 | 14 | 72 | ||
| Short-term investments | 484 | 515 | 321 | 381 | 245 | 328 | 95 | ||
| Other undisclosed cash, cash equivalents, and short-term investments | 153 | 220 | 144 | 32 | 59 | 125 | 27 | ||
| Receivables | (1) | (0) | 5 | 8 | 13 | ||||
| Inventory, net of allowances, customer advances and progress billings | 7 | 1 | ✕ | ||||||
| Inventory | 7 | 1 | |||||||
| Contract with customer, asset | 9 | ✕ | ✕ | ✕ | ✕ | ✕ | |||
| Other undisclosed current assets | (122) | (192) | (123) | (19) | (47) | (121) | (24) | ||
| Total current assets: | 612 | 614 | 445 | 560 | 337 | 360 | 170 | ||
| Noncurrent Assets | |||||||||
| Finance lease, right-of-use asset | 1 | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | ||
| Operating lease, right-of-use asset | 94 | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | ||
| Property, plant and equipment | 31 | 24 | 24 | 25 | 23 | 6 | 4 | ||
| Long-term investments and receivables | 153 | 220 | 144 | 32 | 59 | 125 | 27 | ||
| Long-term investments | 153 | 220 | 144 | 32 | 59 | 125 | 27 | ||
| Restricted cash and investments | 1 | ||||||||
| Other noncurrent assets | 0 | 1 | 2 | 1 | 1 | 0 | |||
| Total noncurrent assets: | 279 | 245 | 169 | 59 | 83 | 132 | 31 | ||
| TOTAL ASSETS: | 891 | 858 | 614 | 619 | 420 | 492 | 201 | ||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 75 | 60 | 57 | 49 | 31 | 31 | 15 | ||
| Accounts payable | 22 | 18 | 23 | 17 | 15 | 11 | 4 | ||
| Accrued liabilities | 53 | 42 | 34 | 32 | 16 | 14 | 7 | ||
| Employee-related liabilities | 6 | 4 | |||||||
| Taxes payable | 1 | ||||||||
| Deferred revenue | 11 | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | ||
| Debt | 7 | ||||||||
| Deferred compensation liability | 0 | ||||||||
| Deferred revenue and credits | ✕ | 1 | 38 | 39 | 22 | 36 | 25 | ||
| Other liabilities | 0 | ||||||||
| Other undisclosed current liabilities | 33 | (6) | (4) | ||||||
| Total current liabilities: | 93 | 94 | 95 | 88 | 53 | 61 | 37 | ||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 107 | ||||||||
| Finance lease, liability | 1 | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | ||
| Operating lease, liability | 106 | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | ||
| Liabilities, other than long-term debt | 51 | 18 | 144 | 172 | 22 | 6 | 33 | ||
| Deferred revenue and credits | ✕ | 18 | 144 | 172 | 22 | 6 | 33 | ||
| Deferred revenue | 51 | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | ||
| Other undisclosed noncurrent liabilities | 60 | ||||||||
| Total noncurrent liabilities: | 157 | 77 | 144 | 172 | 22 | 6 | 33 | ||
| Total liabilities: | 250 | 171 | 239 | 261 | 75 | 68 | 70 | ||
| Stockholders' equity | |||||||||
| Stockholders' equity attributable to parent | 641 | 688 | 376 | 359 | 345 | 424 | 131 | ||
| Common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Additional paid in capital | 2,156 | 1,794 | 1,175 | 842 | 630 | 591 | 245 | ||
| Accumulated other comprehensive income (loss) | 0 | (2) | (1) | (0) | (0) | (0) | 0 | ||
| Accumulated deficit | (1,516) | (1,105) | (798) | (483) | (285) | (167) | (113) | ||
| Total stockholders' equity: | 641 | 688 | 376 | 359 | 345 | 424 | 131 | ||
| Other undisclosed liabilities and equity | 0 | ||||||||
| TOTAL LIABILITIES AND EQUITY: | 891 | 858 | 614 | 619 | 420 | 492 | 201 | ||
Income statement (P&L) ($ in millions)
| 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 118 | 94 | 43 | 70 | 59 | 65 | 26 | |
| Revenue, net | ✕ | ✕ | 43 | 70 | 59 | 92 | 26 | |
| Cost of revenue (Cost of Goods and Services Sold) | (1) | (1) | (0) | (0) | (0) | (0) | ||
| Gross profit: | 117 | 93 | 43 | 70 | 59 | 65 | 25 | |
| Operating expenses | (543) | (457) | (364) | (271) | (178) | (119) | (64) | |
| Other undisclosed operating income | 1 | 0 | 0 | 0 | 0 | |||
| Operating loss: | (426) | (362) | (321) | (201) | (119) | (54) | (39) | |
| Nonoperating income (Investment Income, Nonoperating) | 15 | 16 | 6 | 3 | 1 | 0 | 0 | |
| Other undisclosed income from continuing operations before equity method investments, income taxes | 0 | |||||||
| Loss from continuing operations before equity method investments, income taxes: | (411) | (346) | (315) | (198) | (118) | (54) | (39) | |
| Other undisclosed loss from continuing operations before income taxes | (0) | |||||||
| Loss from continuing operations before income taxes: | (411) | (346) | (315) | (198) | (118) | (54) | (39) | |
| Income tax expense (benefit) | 0 | (1) | ||||||
| Net loss attributable to parent: | (411) | (346) | (315) | (198) | (118) | (54) | (39) | |
| Preferred stock dividends and other adjustments | (4) | |||||||
| Net loss available to common stockholders, diluted: | (411) | (346) | (315) | (198) | (118) | (54) | (44) | |
Comprehensive Income ($ in millions)
| 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (411) | (346) | (315) | (198) | (118) | (54) | (39) | |
| Comprehensive loss: | (411) | (346) | (315) | (198) | (118) | (54) | (39) | |
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | 2 | (1) | (1) | 0 | (0) | (0) | 0 | |
| Comprehensive loss, net of tax, attributable to parent: | (409) | (347) | (316) | (198) | (118) | (54) | (39) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.